Akaike N, Himori N
Department of Pharmacology, Nippon Roche Research Center, Kamakura, Japan.
Naunyn Schmiedebergs Arch Pharmacol. 1993 Jun;347(6):652-7. doi: 10.1007/BF00166949.
To define their efficacy and mechanism of action, the possible antagonistic effects of intravenously administered dextrorphan and dizocilpine, non-competitive N-methyl-D-aspartic acid (NMDA) receptor antagonists, on tonic convulsions and death in a variety of experimental mice models were compared. Dextrorphan not only produced dose-dependent protection against the tonic convulsions caused by an intracerebroventricular injection of NMDA, but also showed a broad spectrum of anticonvulsant activities against tonic convulsions caused by alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainic acid (KA), bicuculline, pentylenetetrazole or electroconvulsive shock. The anticonvulsant action of dizocilpine was found to be more efficacious for any type of tonic convulsions and was 20- to 70-fold more potent than that of dextrorphan. Dizocilpine, unlike dextrorphan, impaired motor function at doses showing its anticonvulsant activity. Bay k-8644 (a Ca2+ channel agonist)-induced seizures were not antagonized by dextrorphan. Dextrorphan and dizocilpine were characteristically selective for protective functions against death, especially with three subtypes of glutamate receptors, as death caused by NMDA but not by AMPA and KA was selectively and markedly inhibited by both dextrorphan and dizocilpine. In view of these results, the efficacy of dextrorphan and dizocilpine as antagonists of convulsant effects appears to be consistent with the interpretation that a variety of convulsants cause tonic convulsions via direct or indirect interaction with the NMDA receptor complex. Furthermore, it is suggested that influx of Ca(2+) and intracellular Ca(2+) activity, such as the Bay k-8644-modulated activation of Ca(2+) binding proteins, are not directly modified by the administration of dextrorphan, itself.
为明确静脉注射右啡烷和地佐环平(非竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂)在多种实验小鼠模型中对强直性惊厥和死亡的可能拮抗作用、疗效及作用机制,进行了比较。右啡烷不仅对脑室内注射NMDA引起的强直性惊厥产生剂量依赖性保护作用,还对α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)、 kainic酸(KA)、荷包牡丹碱、戊四氮或电惊厥休克引起的强直性惊厥表现出广泛的抗惊厥活性。地佐环平的抗惊厥作用对任何类型的强直性惊厥都更有效,其效力比右啡烷高20至70倍。与右啡烷不同,地佐环平在显示其抗惊厥活性的剂量下会损害运动功能。右啡烷不能拮抗Bay k-8644(一种Ca2+通道激动剂)诱导的癫痫发作。右啡烷和地佐环平对死亡具有特征性的保护功能选择性,尤其是对三种亚型的谷氨酸受体,因为右啡烷和地佐环平都能选择性且显著地抑制由NMDA而非AMPA和KA引起的死亡。鉴于这些结果,右啡烷和地佐环平作为惊厥效应拮抗剂的疗效似乎与以下解释一致:多种惊厥剂通过与NMDA受体复合物直接或间接相互作用引起强直性惊厥。此外,提示右啡烷本身的给药不会直接改变Ca(2+)的内流和细胞内Ca(2+)活性,如Bay k-8644调节的Ca(2+)结合蛋白的激活。